(Press-News.org) A team of Japanese scientists have found scientific proof that people doing exercises appear to perform better when another person compliments them. The research was carried out by a group lead by National Institute for Physiological Sciences Professor Norihiro Sadato, Graduate University for Advanced Studies graduate student Sho Sugawara, Nagoya Institute of Technology Tenure-Track Associate Professor Satoshi Tanaka, and in collaboration with Research Center for Advanced Science and Technology Associate Professor Katsumi Watanabe. The team had previously discovered that the same area of the brain, the striatum, is activated when a person is rewarded a compliment or cash. Their latest research could suggest that when the striatum is activated, it seems to encourage the person to perform better during exercises. The paper is published online in PLOS ONE (November 7, 2012, edition).
Forty-eight adults recruited for the study were asked to learn and perform a specific finger pattern (pushing keys on a keyboard in a particular sequence as fast as possible in 30 seconds). Once participants had learned the finger exercise, they were separated into three groups. One group included an evaluator who would compliment participants individually, another group involved individuals who would watch another participant receive a compliment, and the third group involved individuals who evaluated their own performance on a graph. When the participants were asked to repeat the finger exercise the next day, the group of participants who received direct compliments from an evaluator performed better than participants from the other groups. It indicates that receiving a compliment after exercising stimulates the individual to perform better afterwards.
According to Professor Sadato, "To the brain, receiving a compliment is as much a social reward as being rewarded money. We've been able to find scientific proof that a person performs better when they receive a social reward after completing an exercise. There seems to be scientific validity behind the message 'praise to encourage improvement'. Complimenting someone could become an easy and effective strategy to use in the classroom and during rehabilitation."
This research was funded by the Japanese Ministry of Education, Culture, Sports, Science and Technology's Sciences Research Grant (KAKENHI).
### END
A scientific explanation to why people perform better after receiving a compliment
2012-11-09
ELSE PRESS RELEASES FROM THIS DATE:
Understanding antibiotic resistance using crystallography and computation
2012-11-09
Increasingly, bacteria such as E. coli are resisting the action of carbapenems by producing enzymes (carbapenemases) that break a specific chemical bond in the antibiotic, destroying its antimicrobial activity.
Carbapenemases are members of the group of enzymes called beta-lactamases that break down penicillins and related antibiotics, but it has not been clear why carbapenemases can destroy carbapenems while other beta-lactamases cannot.
Using molecular dynamics simulations, Professor Adrian Mulholland in the School of Chemistry and Dr Jim Spencer in the School of ...
ADHD medicine affects the brain's reward system
2012-11-09
A group of scientists from the University of Copenhagen has created a model that shows how some types of ADHD medicine influence the brain's reward system. The model makes it possible to understand the effect of the medicine and perhaps in the longer term to improve the development of medicine and dose determination. The new research results have been published in the Journal of Neurophysiology.
In Denmark approximately 2-3 per cent of school-age children satisfy diagnostic criteria for ADHD, and therefore it is crucial to know how the medicine works. With a new mathematical ...
New mechanism of action for PARP inhibitors discovered
2012-11-09
PHILADELPHIA — New understanding of how drugs called PARP inhibitors, which have already shown promise for the treatment of women with familial breast and ovarian cancers linked to BRCA mutations, exert their anticancer effects has led to the identification of ways in which the patient population that might benefit from PARP inhibitors could be expanded.
Yves Pommier, M.D., Ph.D., chief of the Laboratory of Molecular Pharmacology at the National Cancer Institute's Center for Cancer Research in Bethesda, Md., and colleagues reported these data in Cancer Research, a journal ...
Link found between child prodigies and autism
2012-11-09
COLUMBUS, Ohio - A new study of eight child prodigies suggests a possible link between these children's special skills and autism.
Of the eight prodigies studied, three had a diagnosis of autism spectrum disorders. As a group, the prodigies also tended to have slightly elevated scores on a test of autistic traits, when compared to a control group.
In addition, half of the prodigies had a family member or a first- or second-degree relative with an autism diagnosis.
The fact that half of the families and three of the prodigies themselves were affected by autism is surprising ...
Study questions the relevance of SCIP benchmarks among CABG patients
2012-11-09
(Boston) – Cardiothoracic surgeons and endocrinologists from Boston Medical Center (BMC) have found that among patients undergoing coronary artery bypass graft (CABG) surgery, achieving Surgical Care Improvement Project (SCIP) benchmarks for glycemic control may be irrelevant when perioperative continuous insulin infusion protocols are implemented. These findings appear on-line in the Journal of Thoracic and Cardiovascular Surgery.
Currently, 40 percent of all patients undergoing CABG suffer from diabetes, and this number is quickly rising. Traditionally these patients ...
Belatacept after a kidney transplant: Minor added benefit for certain patients
2012-11-09
Belatacept (trade name Nulojix®) has been approved since June 2011 to prevent a rejection reaction of the body to the donor organ (transplant) in adults who have received a kidney transplant. The Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit of the drug pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG).
The assessment showed an indication of a minor added benefit of belatacept in adults with transplants from donors who had been selected according to the so-called standard criteria. Serious side ...
Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
2012-11-09
Researchers at Moffitt Cancer Center have identified metabolic signatures that may pave the way for personalized therapy in glioma, a type of tumor that starts in the brain.
The study appears online in the October issue of Cancer Research, a publication of the American Association for Cancer Research.
According to the authors, little has been known about the underlying metabolic alterations that may drive the growth of the most aggressive type of glioma, termed glioblastoma.
"For the first time, we have described global metabolomic signatures in glioma," said study ...
Considerable added benefit of ipilimumab in advanced melanoma
2012-11-09
The humanized antibody ipilimumab (trade name Yervoy®) has been approved since August 2011 for the treatment of adult patients with advanced melanoma (black skin cancer) who have already been treated. The term "advanced" means that the melanoma can no longer be removed by an operation or that metastases have formed. The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG). According to the findings, the drug offers major advantages with ...
University of Huddersfield physicist investigates the Big Bang particle
2012-11-09
Scientists at the University of Huddersfield are collaborating with experts at some of the world's leading research institutes in an attempt to unravel the mysteries of a particle that played a role in the creation of the universe.
The existence of neutrinos and anti-neutrinos – particles that are almost massless and which travel at light speed from one side of the earth to the other – was confirmed more than 50 years ago. Scientists believe that they were created at the Big Bang and might hold the key to the nature of the universe.
But they are light particles that ...
Vandetanib in thyroid cancer: No proof of added benefit
2012-11-09
Vandetanib (trade name Caprelsa®) has been approved in Germany since February 2012 for adult patients suffering from a particular form of aggressive thyroid cancer. The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG). According to the findings, there is no proof of added benefit, because no data on patient-relevant outcomes for those patients for whom the drug is approved were presented by the drug manufacturer in its dossier. ...